CN118512442A - 降低血清胆固醇和pcsk9的组合物和方法 - Google Patents

降低血清胆固醇和pcsk9的组合物和方法 Download PDF

Info

Publication number
CN118512442A
CN118512442A CN202410548659.4A CN202410548659A CN118512442A CN 118512442 A CN118512442 A CN 118512442A CN 202410548659 A CN202410548659 A CN 202410548659A CN 118512442 A CN118512442 A CN 118512442A
Authority
CN
China
Prior art keywords
inhibitor
cholesterol
ldl
serum
akr1a1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202410548659.4A
Other languages
English (en)
Chinese (zh)
Inventor
J·S·斯坦勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Case Western Reserve University
Original Assignee
Case Western Reserve University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Case Western Reserve University filed Critical Case Western Reserve University
Publication of CN118512442A publication Critical patent/CN118512442A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202410548659.4A 2017-09-25 2018-09-21 降低血清胆固醇和pcsk9的组合物和方法 Pending CN118512442A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762562784P 2017-09-25 2017-09-25
US62/562,784 2017-09-25
CN201880074862.5A CN111356764B (zh) 2017-09-25 2018-09-21 降低血清胆固醇和pcsk9的组合物和方法
PCT/US2018/052214 WO2019060720A1 (en) 2017-09-25 2018-09-21 COMPOSITIONS AND METHODS FOR REDUCING SERUM CHOLESTEROL AND PCSK9

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201880074862.5A Division CN111356764B (zh) 2017-09-25 2018-09-21 降低血清胆固醇和pcsk9的组合物和方法

Publications (1)

Publication Number Publication Date
CN118512442A true CN118512442A (zh) 2024-08-20

Family

ID=65810650

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202410548659.4A Pending CN118512442A (zh) 2017-09-25 2018-09-21 降低血清胆固醇和pcsk9的组合物和方法
CN201880074862.5A Active CN111356764B (zh) 2017-09-25 2018-09-21 降低血清胆固醇和pcsk9的组合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201880074862.5A Active CN111356764B (zh) 2017-09-25 2018-09-21 降低血清胆固醇和pcsk9的组合物和方法

Country Status (6)

Country Link
US (2) US11576900B2 (cg-RX-API-DMAC7.html)
EP (1) EP3688163A4 (cg-RX-API-DMAC7.html)
JP (2) JP7414712B2 (cg-RX-API-DMAC7.html)
CN (2) CN118512442A (cg-RX-API-DMAC7.html)
CA (1) CA3076889A1 (cg-RX-API-DMAC7.html)
WO (1) WO2019060720A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7414712B2 (ja) * 2017-09-25 2024-01-16 ケース ウエスタン リザーブ ユニバーシティ 血清コレステロールおよびpcsk9を低減する組成物および方法
EP3852750A4 (en) * 2018-09-21 2022-05-11 Case Western Reserve University Aldoketo reductase inhibitors and uses thereof
CN113648427B (zh) * 2021-08-20 2023-07-28 山东大学 透明质酸-es2-af肽偶联物及其制备方法和应用
CN117427170A (zh) * 2023-11-15 2024-01-23 首都医科大学附属北京安贞医院 Krt18蛋白在制备降低胆固醇的药物中的用途

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2683718A (en) 1952-01-11 1954-07-13 Searle & Co Spiro-[xanthene-9, 4'-imidazolidine]-2, 5-dione
JPS58140020A (ja) 1982-02-13 1983-08-19 Nippon Zoki Pharmaceut Co Ltd 脂質代謝改善剤
US4436745A (en) 1982-04-15 1984-03-13 Alcon Laboratories, Inc. Method of inhibiting aldose reductase activity
IL68314A0 (en) * 1982-04-15 1983-07-31 Alcon Lab Inc Method and composition for inhibiting aldose reductase activity and process for preparing spirofluorofluoren and spiro-difluorofluoren compounds
US5153211A (en) 1983-09-14 1992-10-06 Alcon Laboratories, Inc. Spiro-tricyclicaromatic succinimide derivatives as inhibitors of aldose reductase
US20020132845A1 (en) 2000-12-15 2002-09-19 Miller Guy Michael Compositions and methods for the prevention and treatment of tissue ischemia
WO2002098510A1 (en) * 2001-06-07 2002-12-12 Wyeth Combination of a ptpase inhibitor and an aldose reductase inhibitor
EP1431399A1 (en) 2002-12-20 2004-06-23 Clinigenetics Methods and composition for identifying therapeutic agents of atherosclerotic plaque lesions
JP4544503B2 (ja) 2003-04-15 2010-09-15 株式会社アミノアップ化学 雲南苦丁茶成分を含有する組成物
AU2004251690A1 (en) 2003-06-04 2005-01-06 Duke University Compositions and methods for modulating S-nitrosoglutathione reductase
JP2007015924A (ja) 2003-06-12 2007-01-25 Sanwa Kagaku Kenkyusho Co Ltd 抗癌剤耐性を克服する薬剤及びそのスクリーニング方法
US20100292178A1 (en) 2003-07-21 2010-11-18 Jeffrey Young Method of treating non-insulin dependent diabetes mellitus and related complications
US9308206B2 (en) 2004-08-23 2016-04-12 The Board Of Regents Of The University Of Texas System Compositions and methods for treating colon cancer
US20110092566A1 (en) 2004-11-19 2011-04-21 Srivastava Satish K Treatment of cancer with aldose reductase inhibitors
FR2885904B1 (fr) 2005-05-19 2007-07-06 Aventis Pharma Sa Nouveaux derives du fluorene, compositions les contenant et utilisation
WO2007069727A1 (ja) 2005-12-16 2007-06-21 Sanwa Kagaku Kenkyusho Co., Ltd. 急性腎不全の予防または治療剤
EP1987829A4 (en) 2006-02-20 2009-07-29 Sanwa Kagaku Kenkyusho Co PROPHYLACTIC OR THERAPEUTIC AGENT FOR LESIONS DUE TO BRAIN ISCHEMIA OR LESIONS DUE TO BRAIN ISCHEMIA WITH REPERFUSION IN BRAIN VASCULAR ACCIDENTS
JP2010510248A (ja) 2006-11-21 2010-04-02 ビアメト ファーマシューティカルズ,インク. 金属結合部分をターゲティング部分と組み合わせて使用する金属酸化還元酵素阻害剤
US8440617B2 (en) 2007-03-22 2013-05-14 The Trustees Of The University Of Pennsylvania Hyperbaric treatment in wound healing
WO2010104595A1 (en) 2009-03-11 2010-09-16 Xintria Pharmaceutical Corporation, Inc. Methods and compositions for the treatment of metabolic and cardiovascular disorders
EP2295593A1 (en) 2009-09-15 2011-03-16 Philippe Marliere Method for the enymatic production of 3-hydroxy-3-methylbutyric acid from acetone and acetyl-CoA
US20120083501A1 (en) 2010-09-24 2012-04-05 Hunt Kevin W Compounds for treating neurodegenerative diseases
US20150335615A1 (en) * 2013-01-04 2015-11-26 Toshihisa Kawai Cholesterol-lowering compounds in combination with lipid metabolism-altering compounds of non-absorbable sugars, compounds that convert nh3 to nh4+, or hydrogen-generating compounds for the treatment of high cholesterol and inflammation
EP3179995B1 (en) 2014-08-12 2018-11-07 University of Pécs (Pécsi Tudományegyetem) Methods and materials for reducing ischemia-reperfusion injury
EP3226859B1 (en) * 2014-12-05 2025-03-26 Case Western Reserve University Akr1a1 inhibitors for use in lowering cholesterol and modulate s-nitrosylation
US10537557B2 (en) 2016-01-27 2020-01-21 Case Western Reserve University Methods of treating respiratory disorders
JP7414712B2 (ja) * 2017-09-25 2024-01-16 ケース ウエスタン リザーブ ユニバーシティ 血清コレステロールおよびpcsk9を低減する組成物および方法
EP3852750A4 (en) * 2018-09-21 2022-05-11 Case Western Reserve University Aldoketo reductase inhibitors and uses thereof
WO2021061763A1 (en) * 2019-09-23 2021-04-01 Case Western Reserve University Aldoketo reductase inhibitors and uses thereof

Also Published As

Publication number Publication date
EP3688163A4 (en) 2022-12-14
WO2019060720A1 (en) 2019-03-28
JP2020535142A (ja) 2020-12-03
CN111356764A (zh) 2020-06-30
JP7414712B2 (ja) 2024-01-16
CN111356764B (zh) 2024-05-24
US11576900B2 (en) 2023-02-14
JP2024001162A (ja) 2024-01-09
US20230190710A1 (en) 2023-06-22
US20200268717A1 (en) 2020-08-27
EP3688163A1 (en) 2020-08-05
CA3076889A1 (en) 2019-03-28

Similar Documents

Publication Publication Date Title
US20230190710A1 (en) Compositions and methods of reducing serum cholesterol and pcsk9
CN104066731B (zh) 可用作sgc刺激剂的2-苄基、3-(嘧啶-2-基)取代的吡唑类
US10479771B2 (en) Pyridazinone and pyridone compounds
US20230024914A1 (en) Methods of treating respiratory disorders
JP2016540017A (ja) sGC刺激物質
TWI761471B (zh) Atf3誘導化合物
JP2021522247A (ja) 肝疾患における好中球エラスターゼ阻害薬の使用
JP2018048178A (ja) オキサビシクロヘプタン類、および再灌流障害の治療のためのオキサビシクロヘプタン類
US10016397B2 (en) Selective AT2 receptor agonists for use in treatment of cachexia
JP2022105013A (ja) ケモカインの生物活性を中和するためのピリミジノン誘導体およびその使用
CN109476686B (zh) sGC刺激剂的磷前药
US10322132B2 (en) Prevention or treatment of uratic or gouty diseases
WO2003077832A2 (en) Dexanabinol and dexanabinol analogs regulate inflammation related genes
JP2018516275A (ja) ナフトキノン系化合物を含む、膵炎を治療又は予防する組成物
AU2010243314A1 (en) Phosphotetrahydropyran compounds for the treatment of wounds and fibrotic disorders
US20040097539A1 (en) Hsp inductor
JP2023506201A (ja) 化合物及びα1-アンチトリプシン欠損症の治療のためのそれらの使用
WO2012122707A1 (zh) 季铵盐类化合物、其制备方法、药物组合物及用途
US20230097253A1 (en) Novel quinazoline compound as therapeutic agent for metabolic disorders
JP2008538372A (ja) テトラヒドロビオプテリンおよび他の化合物を含んでなる組み合わせ製品

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination